Navigation Links
Anthera Pharmaceuticals Selects the Merck BioManufacturing Network as Manufacturing Supplier for A-623, Anthera's Investigational Novel Peptibody Agent
Date:12/14/2010

used on developing and commercializing products to treat serious diseases associated with inflammation, including cardiovascular and autoimmune diseases. Anthera has one Phase 3 clinical program, A-002, and two Phase 2 clinical programs, A-623 and A-001. A-002 and A-001 inhibit a novel enzyme target known as sPLA2. Elevated levels of sPLA2 have been implicated in a variety of acute inflammatory conditions, including acute coronary syndrome and acute chest syndrome, as well as chronic diseases such as stable coronary artery disease (CAD). Anthera's Phase 2 product candidate, A-623, targets elevated levels of B-lymphocyte stimulator (BAFF) which has been associated with a variety of B-Cell mediated autoimmune diseases, including systemic lupus erythematosus (lupus). For more information, please visit www.anthera.com.

Safe Harbor Statement

Any statements contained in this press release that refer to future events or other non-historical matters are forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These include, but are not limited to, statements relating to the anticipated initiation of Anthera's clinical studies, anticipated duration and expected results of these studies, and the progression of Anthera's products through future stages of clinical development. These forward-looking statements are based on Anthera's expectations as of the date of this press release and are subject to certain risks and uncertainties that could cause actual results to differ materially as set forth in the Company's public filings with the Securities and Exchange Commission, including Anthera's Quarterly Report on Form 10-Q for the quarter ended September 30, 2010. Anthera disclaims any intent or obligation to update any forward-looking statements, whether because of new information, future events or otherwise, except as required by applicable law.<
'/>"/>

SOURCE Anthera Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Anthera Announces Update Call Regarding Vial Problems
2. Anthera Pharmaceuticals Reports 2010 Third Quarter Financial Results and Operational Update
3. Anthera Announces Third Quarter 2010 Financial Report and Conference Call
4. Anthera Pharmaceuticals Announces Pricing of $31.5 Million PIPE Financing
5. Anthera Pharmaceuticals to Present at Deutsche Bank Securities 35th Annual Health Care Conference
6. Anthera Pharmaceuticals Announces Agreement With the FDA on a SPA for Planned Phase 3 Varespladib A-002 Study; Daniel K. Spiegelman Joins Board of Directors
7. Antheras Varespladib Meets Primary Endpoint in Phase 2 FRANCIS Trial for the Treatment of Acute Coronary Syndrome
8. Following Encouraging Results Anthera to Continue IMPACTS Trial for the Prevention of Acute Chest Syndrome in Patients With Sickle Cell Disease
9. Anthera Completes Special Protocol Assessment With FDA and Receives EMEA Scientific Advice on Development Path Toward Varespladib Approval
10. Anthera Pharmaceuticals Advances Global Development Strategy for Varespladib in Patients With Acute Coronary Syndrome With the Initiation of FRANCIS Trial
11. DSMB Supports Continuation of Anthera Phase II Impacts Trial for the Prevention of Acute Chest Syndrome in Patients With Sickle Cell Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2015)... 2015  Mytrus, a technology and services company revolutionizing clinical trials, ... consent has received approval for use by ... the first time e-Consent technology will be used in ... Mytrus was also the first electronic informed ... by the U.S. Food and Drug Administration in 2011. ...
(Date:8/27/2015)... , August 27, 2015 ... announced a private investment in public equity (PIPE) deal, ... $28.4 million in Itamar Medical.   Through ... shareholder of Itamar Medical and will work closely with ... According to the investment agreement, Itamar Medical ...
(Date:8/27/2015)... ATLANTA , August 27, 2015 ... Consortium convened in Boston on ... Consortium in an effort to more fully exploit the ... are applied to brain diseases. "As an ... has a responsibility to assume a leadership role - ...
Breaking Medicine Technology:Britain's National Health Service Approves The Use Of Mytrus Technology For Electronic Informed Consent In Clinical Trials 2Britain's National Health Service Approves The Use Of Mytrus Technology For Electronic Informed Consent In Clinical Trials 3Britain's National Health Service Approves The Use Of Mytrus Technology For Electronic Informed Consent In Clinical Trials 4Britain's National Health Service Approves The Use Of Mytrus Technology For Electronic Informed Consent In Clinical Trials 5Britain's National Health Service Approves The Use Of Mytrus Technology For Electronic Informed Consent In Clinical Trials 6Britain's National Health Service Approves The Use Of Mytrus Technology For Electronic Informed Consent In Clinical Trials 7Viola Private Equity Invests up to $28.4 Million in Itamar Medical and Becomes the Largest Shareholder of the Company 2Viola Private Equity Invests up to $28.4 Million in Itamar Medical and Becomes the Largest Shareholder of the Company 3Viola Private Equity Invests up to $28.4 Million in Itamar Medical and Becomes the Largest Shareholder of the Company 4Viola Private Equity Invests up to $28.4 Million in Itamar Medical and Becomes the Largest Shareholder of the Company 5New Elekta Consortium to Push Frontiers of Linear Accelerator-Based Stereotactic Radiation Therapy for the Brain 2New Elekta Consortium to Push Frontiers of Linear Accelerator-Based Stereotactic Radiation Therapy for the Brain 3
... 13 Escalon Medical Corp. (Nasdaq: ... the fiscal year ended June 30, 2009, included in ... Securities and Exchange Commission on October 13, 2009, contain ... accounting firm. This announcement is being made in compliance ...
... BIOSAFE, Inc. , a company that manufactures and ... are launching in specific markets outside the United States ... Crosstex, new BIOSAFE-treated Ultra Sensitive facemasks begin to ... upon contact, and have further proven to be effective ...
Cached Medicine Technology:Escalon(R) Announces Going Concern Qualification 2BIOSAFE Launching In a New Specially-Treated Facemask Effective Against H1N1 Influenza 2BIOSAFE Launching In a New Specially-Treated Facemask Effective Against H1N1 Influenza 3BIOSAFE Launching In a New Specially-Treated Facemask Effective Against H1N1 Influenza 4
(Date:8/27/2015)... ... August 27, 2015 , ... StayWell, a leading provider of ... is ICD-10 ready and available to all clients. All Krames Patient Education content ... are more targeted and return a more comprehensive data set of content than ...
(Date:8/27/2015)... ... August 27, 2015 , ... Banc Intranets recently entered into a ... enable both Johnson City, Tenn.-based firms to work synergistically to promote similar products to ... that caters to organizations in the financial, commercial and services sectors. The software, which ...
(Date:8/27/2015)... ... August 27, 2015 , ... Susan Harris ... to relieve vaginal discomfort due to pre- and post-menopause, chemotherapy, and child birth. , ... laser, which delivers controlled energy to the vaginal tissue, revitalizing cells so they make ...
(Date:8/27/2015)... , ... August 27, 2015 , ... ... and development solutions for drugs, biologics and consumer health products, today announced that ... upcoming FlyPharma Conference, to be held at the Radisson Blu Edwardian Hotel, London ...
(Date:8/27/2015)... , ... August 27, 2015 , ... ... communities in and around Birmingham Alabama, is launching a joint charity drive with ... in the Birmingham area qualify for assistance programs, and many lack the simple ...
Breaking Medicine News(10 mins):Health News:StayWell announces all health content is ICD-10 ready 2Health News:StayWell announces all health content is ICD-10 ready 3Health News:Banc Intranets Forms Strategic Marketing Partnership with All Clear System 2Health News:Banc Intranets Forms Strategic Marketing Partnership with All Clear System 3Health News:Banc Intranets Forms Strategic Marketing Partnership with All Clear System 4Health News:LifeStream Health Centre & MedSpa Announces New Treatment for Vaginal Discomfort 2Health News:LifeStream Health Centre & MedSpa Announces New Treatment for Vaginal Discomfort 3Health News:Clinical Trial Supply Chain Logistics to be Discussed By Catalent Expert at Upcoming Flypharma Conference 2Health News:Standifer Insurance Group Initiates Charity Drive to Provide School Supplies for Underprivileged Meadow View Elementary Students 2Health News:Standifer Insurance Group Initiates Charity Drive to Provide School Supplies for Underprivileged Meadow View Elementary Students 3
... AHF,s First in Kenya, is US AIDS Group,s 39th ... New Kenyan Partnership Will, Provide Life- saving Anti-retroviral Therapy ... Kenya, where the National HIV/AIDS Prevalence ... Oct. 3 AIDS,Healthcare Foundation (AHF), has joined together ...
... Inc. ("Knopp"),announced that Cheryl Fossum Graham, M.D., F.C.P., ... regulatory and development strategy. (Logo: http://www.newscom.com/cgi-bin/prnh/20070924/KNOPPLOGO ... 28 years of experience in public and,commercial regulatory ... Administration and responsibility for global regulatory affairs at,Pfizer ...
... Acute Success Rate for Catheter Ablation Procedures Performed with ... European Society of Cardiology Congress, ST. LOUIS, Oct. ... by Xu Chen, M.D., of the,Rigshospitalet at the University ... patients treated for atrial fibrillation with the Niobe(R),magnetic navigation ...
... Calif., Oct. 3 /PRNewswire/ Awakening(R) Mineral Therapies for,Healthy ... care,products, is slinging mud in support of October ... and salons across California are invited to,participate in ... patented mud masque, Awakening SCALP(TM), helps to,stimulate follicle ...
... the opening of Eurospine conference in ... ... OFIX ) (the Company) today announced it has,acquired the rights to all ... is designed to alleviate the leg and back pain suffered by,individuals with ...
... Hamilton, ON (Oct. 1, 2007) Lower muscle mass and ... older. , While exercise is a proven way to ... by McMaster researcher Dr. Mark Tarnopolsky shows that taking a ... in addition to resistance exercise training provides even greater benefits. ...
Cached Medicine News:Health News:AHF and Kenya Medical Research Institute Partner to Save Lives at Free AIDS Treatment Clinic in Mombasa 2Health News:AHF and Kenya Medical Research Institute Partner to Save Lives at Free AIDS Treatment Clinic in Mombasa 3Health News:Cheryl Fossum Graham Joins Knopp Neurosciences as Head of Regulatory and Development Strategy 2Health News:Cheryl Fossum Graham Joins Knopp Neurosciences as Head of Regulatory and Development Strategy 3Health News:Stereotaxis Highlights New Data on Acute Success in AFib Treatments With Niobe Magnetic Navigation System 2Health News:Stereotaxis Highlights New Data on Acute Success in AFib Treatments With Niobe Magnetic Navigation System 3Health News:California Company Slings Mud for Breast Cancer Awareness 2Health News:Orthofix International Acquires InSWing(TM) Interspinous Process Spacer 2Health News:Orthofix International Acquires InSWing(TM) Interspinous Process Spacer 3
... Precision Dynamics Corporation offers a ... serving infants to adults. Armboard ... non-woven material assuring easy cleaning ... cross contamination. Choose from three ...
The Side Rail Socket fits all American-made tables with standard side rails. Fits accessories with flat mounting posts up to 1/4"W x 1"L. Attaches at rail ends or notches....
Stainless steel construction to withstand sterilization modalities (EtO, Steris®, and Sterrad®) Wide angle of view...
Stainless steel construction to withstand sterilization modalities (autoclave, EtO, Steris®, and Sterrad®) Fully autoclavable, with both distal and proximal ends uniquely soldered for longe...
Medicine Products: